Single dose pharmacokinetics of auranofin in rheumatoid arthritis.
Six rheumatoid arthritis (RA) patients were given 2 6 mg doses of auranofin (AF) containing Au195, 6 months apart. The radioactivity in the whole body and in plasma, urine, and stool samples was measured for 6 months after each dose. Absorption was rapid with peak plasma concentrations occurring 1.2-2 h post administration. 195Au plasma half-lives (t1/2) ranged from 11.0-31.3 days, with 195Au detectable in plasma for about 80 days. Total body t1/2 averaged 69.2+/-29.7 days. Urinary excretion accounted for 15% of the dose. Cumulative stool excretion was 89%, although 72% was excreted in 10 days. Continued stool excretion over 6 months suggested a "central-enteric" component to the excretory route.
D000042:Absorption; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism*; D001310:Auranofin; D006051:Aurothioglucose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D005243:Feces / Q000032:analysis; D005260:Female; D006046:Gold / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood / Q000652:urine; D006050:Gold Radioisotopes; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged
D006050:Gold Radioisotopes; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold